Assembly Biosciences - 14 Year Stock Split History | ASMB

Stock split history for Assembly Biosciences since 2010. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Assembly Biosciences Annual Stock Splits
Assembly Biosciences Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.074B $0.007B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $14.585B 5.27
Dr Reddy's Laboratories (RDY) India $11.835B 18.71
Aspen Pharmacare (APNHY) South Africa $4.900B 0.00
BridgeBio Pharma (BBIO) United States $4.401B 0.00
Bausch Health Cos (BHC) Canada $3.128B 2.44
Amphastar Pharmaceuticals (AMPH) United States $2.004B 13.71
Supernus Pharmaceuticals (SUPN) United States $1.656B 0.00
Taysha Gene Therapies (TSHA) United States $0.439B 0.00
Generation Bio (GBIO) United States $0.199B 0.00
Personalis (PSNL) United States $0.066B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.026B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00